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Abstract: Kidney transplant recipients frequently suffer from skin infections and malignancies,
possibly due to the effects of long-term immunosuppressive therapy. While the relationships between
immunosuppression and these pathological conditions have been widely investigated, little is known
about the relative incidence and characteristics of inflammatory skin diseases in this type of patient.
In this study, we analyze the incidence of a number of inflammatory cutaneous diseases in a cohort
of patients who underwent kidney transplantation. Although our study shows a relatively low
incidence of these pathologies in transplanted patients—in agreement with the general action of
immunosuppressant therapies in reducing inflammation—we scored a different efficacy of the various
immunosuppressive regimens on inflammatory and autoimmune skin diseases. This information can
be key for designing immunosuppressive regimens and devising accurate follow-up protocols.
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1. Introduction
Patients with chronic renal insufficiency often suffer from pathological conditions such as
skin dryness, alopecia, skin discoloration, hair and nail abnormalities, as well as cutaneous
diseases specifically related to kidney failure [1–4]. Usually, in the months immediately
following transplantation, there is a progressive regression of these conditions, with a clinical and
histopathological normalization of the skin [5]. However, other cutaneous diseases may progressively
develop, which afflict more than half of renal transplant recipients, including infections to different
body districts and non-melanoma skin cancers; these side effects are iatrogenic and develop as
a consequence of the long-term immunosuppressive treatment. Notably, inflammatory diseases
of the skin are rarely reported [6], possible as a consequence of the direct therapeutic effect of
immunosuppressive therapy on these diseases. In the most recent Oxford series of kidney transplant
recipients [6], the prevalence of psoriasis and atopic dermatitis was very low, around 1.5%, as also
reported in other case series [7,8]. This is not surprising, since cyclosporine is commonly used in the
treatment of psoriasis and other inflammatory dermatoses [9], while tacrolimus and mycofenolate are
currently proposed for the treatment of atopic dermatitis [10].
Here, we describe the experience of our Clinical Units regarding the incidence and characteristics
of various inflammatory skin diseases in a cohort of kidney transplant recipients, followed-up from
2009 to 2016.
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2. Results
We analyzed the records obtained from a cohort of 610 renal transplant recipients (230 females,
380 males) followed-up at our center from January 2009 to April 2016. The median age was 60 years,
while the mean age was 59. Clinical characteristics of these patients and the type of immunosuppressive
regimen are summarized in Table 1, together with data about the prevalence of cutaneous diseases
in this cohort. According to the treatment schedule in use at our center, the majority of patients (491,
81.5%) received an immunosuppressive regimen without mTOR inhibitors (mTOR-Is), whereas the
remaining 19.5% (119 patients) received sirolimus or everolimus.
Table 1. Incidence of cutaneous diseases in a cohort of kidney transplant recipients.
Variable Number %
Gender
Male 380 62%
Female 230 37.7%
Immunosuppressive treatment
Including mTOR-Is 119 19.5%
Without mTOR-Is 491 81.5%
Skin infections 187 30.7%
Viruses 72
Mycoses 57
Bacterial 28
Mixed 30
Skin cancer 191 31%
Basal Cell Carcinoma (BCC) 94
Squamous Cell Carcinoma (SCC) 51
Melanoma 16
Kaposi’s Sarcoma 17
Cutaneous T cell lymphoma (CTCL) 4
others 9
Inflammatory diseases 88 14.4%
In our series, the most frequent dermatological diseases were skin infections, observed in
187 patients (30.7%), of which there were 72 virus-related infections (Human Papilloma Virus-HPV,
Varicella Zoster Virus-HZV, Herpes Simplex Virus-HSV type 1 and 2), 57 cases of cutaneous mycosis
(Tinea unguium, Pytiriasis versicolor and Tinea corporis), and 28 bacterial infections (folliculitis and
impetigo), while 30 patients had concomitant viral and fungal infections.
A diagnosis of skin cancer during follow-up was made in 191 cases (31.3%); according to the
histological type, we scored basal cell carcinomas (BCCs) in 84 patients, squamous cell carcinomas
(SCCs) in 51, melanomas in 16, Kaposi’s Sarcoma in 17, cutaneous T-cell lymphomas (CTCLs) in four
and other skin tumors in nine.
2.1. Inflammatory Diseases
Among the 610 kidney transplant recipients of our series, 88 showed an inflammatory skin
disease (14.4%). Table 2 summarizes their clinical characteristics, together with data about the time
and type of immunosuppressive regimen. Twenty-six patients were female (29.5%) and 62 were male
(70.5%). The median age was 47 years, whereas no differences were found in the median duration
of immunosuppression (9.1 years) and the follow-up duration with respect to the rest of our series.
The immunosuppressive schedule included tacrolimus in 54 patients (61.4%) and cyclosporine in 21
(23.9%). Inflammatory skin conditions were diagnosed in 16.8% (21 of 119) of the patients treated
with mTOR-Is and in 13.8% (67 of 489) of the patients that were subject to treatment regimens without
mTOR-Is. These differences did not achieve a statistical significance.
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Table 2. Clinical characteristics of kidney transplant recipients affected by inflammatory skin diseases.
Variable Number %
Gender
Male 62 70.5%
Female 26 29.5%
Median age 47 years
Median immunosuppression 9.1 years
Concomitant diagnosis
Skin infections 29 33%
Viruses 12
Mycoses 9
Bacterial 5
Mixed 3
Skin cancer 24 27.3%
BCC 11
SCC 9
Melanoma 2
Kaposi’s Sarcoma 2
Infective skin diseases were observed in 29 out of 88 patients (33%), of which 12 were viruses
(HPV, VZV, HSV 1 and 2), nine were cutaneous mycoses (Tinea unguium, pytiriasis versicolor and tinea
corporis), and five were bacterial infections (folliculitis and impetigo); three patients had concomitant
viral and fungal infections.
Clinical details of the three groups of patients can be described as follow.
2.1.1. Psoriasis
We detected psoriasis-related skin conditions in a total of 14 out of 610 patients (2.3%). In all cases,
diagnosis was made before the onset of the renal failure. Psoriasis in renal transplant recipients was
characterized by a minimal skin involvement (Psoriasis Area Severity Index—PASI score < 3) (Figure 1)
and did not require active treatment in addition to the on-going immunosuppressive treatment. The
only added treatment was the use of topical emollients in about 30% of cases.
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Notably, the skin areas usually affected were the elbow, knee and scalp regions, whereas the
involvement of other cutaneous areas or the presence of plaque lesions was extremely rare. No cases
of pustular, palmo-plantar or generalized psoriasis were scored.
In two cases of our series, patients reported a clinical improvement of psoriatic lesions after the
beginning of the immunosuppressive treatment, in comparison to the pre-transplant period.
2.1.2. Atopic Dermatitis and Related Skin Conditions
Atopic lesions were observed in 43 out of 610 cases (7.1%) (Figure 2). Atopic dermatitis was
detected in an extremely low percentage of renal transplant recipients, i.e., three cases out of 610 (0.5%).
Other atopic-related skin conditions (such as seborrheic dermatitis, nummular eczema, and allergic
contact dermatitis) were found in 40 of 610 cases (6.6%). Seborrheic dermatitis (Figure 3) was the most
frequent atopic-related skin disorder with a total of 37 cases (86%).
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In the majority of patients with atopic and atopic-related skin conditions, emollients were the only
topical treatment proposed. No patients required an adjustment of the immunosuppressive treatment
to control atopic-related skin conditions.
2.1.3. Other Inflammatory Skin Conditions
Besi e atopic dermatitis or ps r asis, 31 patients out of 610 cases (5%) developed other dermatitis.
Among thes , the most c mm n condition reported was rurigo nodularis (45.2%) (Figure 4), followed
by minor aphto is (20.7%). The other inflammatory condi ions detected in our series were reported in
Table 3.
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Statistical analyses did not identify clinical and/or epidemiological features significantly
associated with the development of inflammatory skin disease.
Of note, in our group of patients, 24 (27.3%) reported a skin cancer (11 BCCs, nine SCCs, two
melanomas, two Kaposi Sarcomas) after transplantation. No differences in the prevalence of skin
cancers were found in the three sub-groups of patients.
3. Discussion
Numerous studies have pointed out that skin infections and Non Melanoma Skin Cancers
(NMSCs) are commonly occurring complications for transplant recipients [6,8,11–14] due to the
long-term immunosuppression used to prevent transplant rejection. Conversely, scant clinical data
are available regarding the incidence of inflammatory skin diseases in patients with solid organ
transplantation (Table 4). In a previous study performed to evaluate the incidence of cutaneous
diseases in a group of 282 kidney transplant recipients, we reported that inflammatory conditions
occur in 14.9% of patients [14], in agreement with previous studies [6,7]; an even lower occurrence of
inflammatory diseases in transplanted patients was scored by [8], with only a few cases of acneiform
eruptions, rosacea, asteatotic eczema, contact eczema and stasis dermatitis. Notably, the incidence of
skin diseases with an immunologic pathogenesis is considered to be an even more uncommon event,
with only a few sporadic cases reported [14,15]. Many immunosuppressive drugs—such as tacrolimus,
cyclosporine, and mycophenolate—are approved both for preventing chronic transplant rejection and
for the treatment of inflammatory skin diseases [9,15–17]; this dual therapeutic role can easily explain
the observed reduced incidence of inflammatory skin diseases in transplant recipients. In the present
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study, we observed inflammatory skin diseases in less than 15% of our kidney transplant recipients,
versus a more than 60% incidence in the general population [14]. We were not able to identify specific
clinical or epidemiological characteristics in patients with inflammatory dermatological diseases, with
the exception of a prevalence of males, which, however, is in agreement with the general characteristics
of our cohort.
Table 4. Inflammatory cutaneous diseases in solid organ transplant recipients (literature data).
Reference Clinical Characteristics Median Follow-up Cutaneous Disease Numberof Cases
Coehn et al., 1986 [11] 580/kidney 12.2 years Inflammatorydermatoses 32 (5.5%)
Hoover et al., 2007 [18] 1/liver; Male Not Available Psoriasis 1
Kaaroud et al., 2007 [19] 1/kidney; Female 31-year-old 31 months Pustular psoriasis 1
Collazo et al., 2008 [20] 1/liver; Male 49-year-old Not Available Psoriasis 1
Brokalaki et al., 2009 [21]
1/ kidney + pancreas 7 years Psoriasis 1Male 42-year-old
Wisgerhof et al., 2009 [12] 2136/kidney + pancreas 10.2 years
Psoriasis 4 (0.2%)
Atopic-related dermatitis 58 (2.7%)
Others 56 (2.6%)
Lally et al., 2010 [6] 308/kidney; median age 51 years 10.7 years
Psoriasis 5 (1.6%)
Atopic dermatitis 4 (1.3%)
Seborrhoeic dermatitis 29 (9.4%)
Saalman et al., 2010 [22] liver Not Available Orofacialgranulomatosis 8
Savoia et al., 2011 [14] 282/kidney; median age 59 years 7.2 years
Psoriasis 17 (6%)
Atopic-related dermatitis 25 (8.8%)
Shroff et al., 2012 [23] 176/liver; median age 16 mo 19 months Atopic dermatitis 24 (13.6%)
Bumbacea et al., 2013 [24] 1/liver; Male six-year-old 2 years Atopic dermatitis 1
Moretti de Lima et al., 2013 [8] 53/kidney; median age 44 year >5 years (52.8%)
Atopic-related dermatitis 4 (7.5%)
Others 7 (13.2%)
Foroncewicz et al., 2014 [25] 591/liver; median age 50 year 8.5 years Psoriasis 10 (1.6%)
Machura et al., 2015 [26] 1/heart; Male three-year-old 2.5 years Atopic dermatitis 1
Madankumar et al., 2015 [27] 1/liver; Female 52-year-old 5 years Psoriasis 1
The most common inflammatory disease scored in our transplanted patients was seborrheic
dermatitis, which affected a total of 37 patients, accounting for 86% of those with atopic-related
skin diseases. This finding is consistent with a previous study [6], but in apparent contrast with the
fact that most patients of our series are receiving tacrolimus, commonly used to manage seborrhoeic
dermatosis [28]. A possible explanation for this paradoxical behavior could be that only a percentage of
seborrhoeic patients are full responders to tacrolimus [28], similarly to those affected by psoriasis [27].
In addition, despite tacrolimus activity in the treatment of atopic dermatitis, a number of
atopic dermatitis cases in children with solid organ transplantation have been recently observed:
(i) Bumbacea and Ghiordanescu [24] described a six-year old patient who developed a “de novo” atopic
dermatitis during long-term immunosuppression with tacrolimus following liver transplantation;
(ii) Machura et al. [27] reported a similar case in a three-year-old boy treated with tacrolimus and
mycofenolate after heart transplantation. The pathogenesis of this post-transplantation condition is
not completely understood and probably involves several factors, including a tacrolimus-induced
increase in intestinal permeability, facilitating the absorption of potential allergens and promoting the
development of allergy [27]. In our case study, atopic dermatitis was detected in an extremely low
percentage of renal transplant recipients, i.e., in three cases out of 610 (0.5%). This can be explained
on the basis of the characteristics of our cohort, which was only composed of adult subjects: it is
well known that the majority of transplanted patients with atopic dermatitis are children and that
a significant risk factor for atopic disease during the post-transplant period is represented by the
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age of the donor and/or recipient [29]; moreover, allergies are less common described after renal
transplantation [30,31].
We also observed a very low percentage of patients affected by psoriasis. The low PASI
score confirms that, in the majority of cases, no specific treatment was required in addition to the
immunosuppressive regimen to manage psoriatic symptoms. This is possibly due to the high efficacy
of calcineurin inhibitors in suppressing psoriasis: we actually observed tacrolimus and cyclosporine
efficacy in 61.4% and 23.9% of kidney transplant recipients, respectively. Actually, the therapeutic
value of tacrolimus in the treatment of psoriasis was firstly described in transplanted patients [32] and
then confirmed in randomized trials [33,34]. Similarly, the effectiveness of cyclosporine in psoriasis
has been observed in immunocompetent [34,35] as well as in transplanted patients [22]. Calcineurin
inhibitors block the transcription of genes controlling the expression of cytokines, primarily IL-2, and
also exert a negative action on regulatory T cell activation (CD4+CD25+FOXp3) [36]. However, a small
subset of transplanted patients—especially those who have had a liver transplant—has severe psoriasis
that does not fully respond to immunosuppression [22,37,38]. This could be explained by the fact that
common immunosuppressive regimens do not completely inhibit all the inflammatory pathways of
this pathologic condition, especially the TNF-α and the IL17/23 pathways [24]
Moreover, some authors reported a possible role of mTOR-Is in the pathogenesis of inflammatory
skin lesions in kidney transplant recipients [21,29–31,36]. In our series, 119 of 610 (19.5%) patients were
being treatment by mTOR-Is. Among these patients, the incidence of inflammatory skin conditions
was 16.8%, whereas in patients treated with immunosuppressive regiments without mTOR-Is this
percentage was 13.8%; even if a trend could be hypothesized, this difference did not achieve a
statistical significance.
4. Materials and Methods
4.1. Patients
Data about 610 renal transplant recipients with a dermatological follow-up at our centers
were recorded from January 2009 to April 2016. Sixty-two percent of these patients were males,
while 38% were females; median age at transplantation was 51 years and the median duration of
immunosuppression was 9.1 years. The median follow-up duration was nine years. For each patient,
we evaluated the presence of inflammatory dermatological diseases, which were classified in the
following three categories: (i) psoriasis; (ii) atopic dermatitis and related skin conditions (including
seborrheic dermatitis, allergic contact dermatitis, and nummular eczema); (iii) other inflammatory
dermatitis, unrelated to psoriatic as well as to atopic conditions.
4.2. Statistical Analysis
Statistical analysis was performed by IBM SPSS Statistics software (IBM Corp., Armonk, NY, USA)
and Kaplan-Meier curves (MedCalc Software, Ostend, Belgium).
5. Conclusions
In conclusion, our work emphasizes the low incidence of skin diseases with autoimmune or
inflammatory pathogenesis in solid organ-transplanted patients, correlating the beneficial therapeutic
effect of these immunosuppressive regimens to the various types of skin disorders.
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